Translational Development of Microbiome-Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates-Reference-Cited by-同舟云学术

Translational Development of Microbiome-Based Therapeutics: Kinetics of E. coli Nissle and Engineered Strains in Humans and Nonhuman Primates

Published:2017-12-01 Issue:2 Volume:11 Page:200-207
ISSN:1752-8054
Container-title:Clinical and Translational Science
language:en
Short-container-title:Clinical And Translational Science

Author:

Kurtz Caroline¹,Denney William S.²,Blankstein Larry¹,Guilmain Sarah E.¹,Machinani Suman¹,Kotula Jonathan¹,Saha Saurabh³,Miller Paul¹,Brennan Aoife M.¹

Affiliation:

1. Synlogic; Cambridge Massachusetts USA

2. Human Predictions; Cambridge Massachusetts USA

3. Atlas Venture; Cambridge Massachusetts USA

Publisher

Wiley

Subject

General Pharmacology, Toxicology and Pharmaceutics,General Biochemistry, Genetics and Molecular Biology,General Medicine,General Neuroscience

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/cts.12528/fullpdf

Reference23 articles.

1. Insights from 100 years of research with probiotic E. coli;Wassenaar;Eur. J. Microbiol. Immunol,2016

2. Survival of the probiotic Escherichia coli Nissle 1917 (EcN) in the gastrointestinal tract given in combination with oral mesalamine to healthy volunteers;Joeres-Nguyen-Xuan;Inflamm. Bowel Dis,2010

3. Effect of administration of Escherichia coli Nissle (Mutaflor) on intestinal colonization, endotoxemia, liver function and minimal hepatic encephalopathy in patients with liver cirrhosis;Lata;Vnitr. Lek,2006

4. Voluntarily exposure to a single, high dose of probiotic Escherichia coli results in prolonged colonisation;Wassenaar;Benef. Microbes,2014

5. Specific proliferative and antibody responses of premature infants to intestinal colonization with nonpathogenic probiotic E. coli strain Nissle 1917;Cukrowska;Scand. J. Immunol.,2002

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Benefits and concerns of probiotics: an overview of the potential genotoxicity of the colibactin-producing Escherichia coli Nissle 1917 strain;Gut Microbes;2024-09-04

2. Synthetic extremophiles via species-specific formulations improve microbial therapeutics;Nature Materials;2024-07-05

3. Daily oral administration of probiotics engineered to constantly secrete short-chain fatty acids effectively prevents myocardial injury from subsequent ischaemic heart disease;Cardiovascular Research;2024-06-08

4. Targeted delivery of the probiotic Saccharomyces boulardii to the extracellular matrix enhances gut residence time and recovery in murine colitis;Nature Communications;2024-05-06

5. Rational Engineering of Escherichia coli Nissle 1917 as Live Biotherapeutic to Degrade Uremic Toxin Precursors;ACS Synthetic Biology;2024-04-08